Phage microarray profiling of the humoral response to disease

Patent metadata

Field	Value
Publication number	US-9267133-B2
Application number	US-91446510-A
Country	US
Kind code	B2
Filing date	Oct 28, 2010
Priority date	Jun 9, 2004
Publication date	Feb 23, 2016
Grant date	Feb 23, 2016

Abstract

The present invention relates to compositions and methods for cancer diagnostics, including but not limited to, cancer markers. In particular, the present invention provides methods and compositions for phage microarray profiling of cancer (e.g., prostate, lung, or breast cancer). The present invention further provides novel markers useful for the diagnosis, characterization, and treatment of cancers.

First claim

We claim:

1. A panel for detecting autoantibodies indicative of cancer from a subject, the panel comprising two or more tumor antigens, wherein at least one of said tumor antigens comprises an amino acid sequence comprising SEQ ID NO. 407 or SEQ ID NO. 402 wherein each of said tumor antigens is attached to a surface.

2. The panel of claim 1 , wherein said cancer is lung, breast or prostate cancer.

3. A kit comprising two or more reagents, each of which is adapted to specifically detect the presence or absence of a humoral response to a tumor antigen, wherein at least one of said reagents is adapted to specifically detect the presence or absence of a humoral response to a tumor antigen comprising an amino acid sequence comprising SEQ ID NO: 407 or SEQ ID NO: 402.

4. The kit of claim 3 , further comprising a reagent adapted to specifically detect the presence or absence of a humoral response to a tumor antigen from BRD2, HES1, eIF4G1, or heat shock 70 kDa protein 8 (HSPA70).

5. The kit of claim 4 , wherein at least one of said reagents comprises an antigen, antibody, protein, peptide, peptidomimetic, peptoid, or small molecule.

6. The kit of claim 4 , wherein at least one of said two or more reagents is specific for an autoantibody.

7. The kit of claim 4 , wherein at least one of said two or more reagents detects a humoral response in sera from a cancer sample.

8. The kit of claim 4 , wherein at least one of said two or more reagents does not detect a humoral response in sera from a control sample.

9. The reagent of claim 7 , wherein said cancer is lung, breast or prostate cancer.

10. A kit comprising a plurality of reagents, each of which is adapted to specifically detect the presence or absence of a humoral response to a tumor antigen, wherein said plurality of reagents is adapted to specifically detect the presence or absence of a humoral response to tumor antigens comprising an amino acid sequence from FAM53B, SEQ ID NO: 402, zinc finger 292, and SEQ ID NO: 407.

11. The kit of claim 10 , wherein at least one of said plurality of reagents comprises an antigen, antibody, protein, peptide, peptidomimetic, peptoid, or small molecule.

12. The kit of claim 10 , wherein at least one of said plurality of reagents is specific for an autoantibody.

13. The kit of claim 10 , wherein at least one of said plurality of reagents detects a humoral response in sera from a cancer sample.

14. The kit of claim 10 , wherein at least one of said plurality of reagents does not detect a humoral response in sera from a control sample.

15. The kit of claim 13 , wherein said cancer is prostate cancer.

16. The kit of claim 10 , further comprising instructions for using said plurality of reagents to detect a cancer.

17. The kit of claim 3 , further comprising instructions for using said plurality of reagents to detect a cancer.

18. The panel of claim 1 , wherein each of said tumor antigens is expressed, individually, on the surface of a phage, wherein said tumor antigens are attached to said surface via said phage.

19. The panel of claim 1 , wherein said plurality of tumor antigens is attached to said surface in an array.

20. The panel of claim 19 , wherein said array is a microarray.

21. The panel of claim 1 , wherein said surface is on a bead.

22. The panel of claim 1 , wherein said surface is glass.

23. The panel of claim 1 , wherein said two or more tumor antigens further comprise a tumor antigen comprising an amino acid sequence from: Family with sequence similarity 53, member B (FAM53B), Ubiquilin, Zinc finger 292, Doublecortin and CAM kinase-like 1 (DCAMKL1), Ribosomal Protein L22 (RPL22), Ribosomal ProteinL 13A (RPL13A), Nucleolar protein 3 (NOL3), or Alpha-2-glycoprotein 1 (AZGP1).

24. The panel of claim 1 , wherein said at least one tumor antigen comprises said amino acid sequence comprising SEQ ID NO:402.

25. The kit of claim 3 , further comprising a reagent adapted to specifically detect the presence or absence of a humoral response to a tumor antigen from: Family with sequence similarity 53, member B (FAM53B), Ubiquilin, Zinc finger 292, Doublecortin and CAM kinase-like 1 (DCAMKL1), Ribosomal Protein L22 (RPL22), Ribosomal ProteinL 13A (RPL13A), Nucleolar protein 3 (NOL3), or Alpha-2-glycoprotein 1 (AZGP1).

26. The kit of claim 3 , wherein at least one of said reagents is adapted to specifically detect the presence or absence of a humoral response to said tumor antigen comprising an amino acid sequence comprising SEQ ID NO: 402.

Assignees

• Chinnaiyan Arul
• Wang Xiaoju
• Univ Michigan

Inventors

• Chinnaiyan Arul
• Wang Xiaoju

Classifications

• G01N33/57555

  of the prostate · CPC title

• G01N33/57515

  of the breast · CPC title

• G01N33/5752

  of the lungs · CPC title

• C12N15/1037 Primary

  Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display · CPC title

• C12Q1/6886

  for cancer (immunoassay for cancer G01N33/575) · CPC title